

Simone Engelender

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1149779/publications.pdf>

Version: 2024-02-01

67
papers

12,789
citations

94381

37
h-index

110317

64
g-index

68
all docs

68
docs citations

68
times ranked

24322
citing authors

#	ARTICLE	IF	CITATIONS
1	Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?. <i>Movement Disorders</i> , 2022, 37, 1346-1359.	2.2	11
2	BMP5/7 protect dopaminergic neurons in an α -synuclein mouse model of Parkinson's disease. <i>Brain</i> , 2021, 144, e15-e15.	3.7	11
3	ATAD3B is a mitophagy receptor mediating clearance of oxidative stress-induced damaged mitochondrial DNA. <i>EMBO Journal</i> , 2021, 40, e106283.	3.5	44
4	SUMOylation in α -Synuclein Homeostasis and Pathology. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 167.	1.7	16
5	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 153.	3.1	76
6	Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. <i>Human Molecular Genetics</i> , 2019, 28, 3982-3996.	1.4	19
7	The NMDA receptor activation by D-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20736-20742.	3.3	89
8	Glycation potentiates α -synuclein-associated neurodegeneration in synucleinopathies. <i>Brain</i> , 2017, 140, 1399-1419.	3.7	153
9	SUMOylation and ubiquitination reciprocally regulate α -synuclein degradation and pathological aggregation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13176-13181.	3.3	131
10	The Threshold Theory for Parkinson's Disease. <i>Trends in Neurosciences</i> , 2017, 40, 4-14.	4.2	153
11	AF-6 Protects Against Dopaminergic Dysfunction and Mitochondrial Abnormalities in <i>Drosophila</i> Models of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 241.	1.8	15
12	Ubiquitination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. <i>Nature Communications</i> , 2016, 7, 11792.	5.8	56
13	The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. <i>Human Molecular Genetics</i> , 2016, 25, 3476-3490.	1.4	108
14	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
15	Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models. <i>Human Molecular Genetics</i> , 2016, 25, 672-680.	1.4	19
16	Convergence of Parkin, PINK1, and α -Synuclein on Stress-induced Mitochondrial Morphological Remodeling. <i>Journal of Biological Chemistry</i> , 2015, 290, 13862-13874.	1.6	76
17	The alanine-serine-cysteine (Asc) transporter controls glycine levels in the brain and is required for glycinergic inhibitory transmission. <i>EMBO Reports</i> , 2015, 16, 590-598.	2.0	48
18	α -Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 630-637.	0.8	24

#	ARTICLE	IF	CITATIONS
19	Site-Specific Differences in Proteasome-Dependent Degradation of Monoubiquitinated α -Synuclein. <i>Chemistry and Biology</i> , 2013, 20, 1207-1213.	6.2	40
20	AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease. <i>Human Molecular Genetics</i> , 2013, 22, 2083-2096.	1.4	25
21	α -Synuclein fate. <i>Autophagy</i> , 2012, 8, 418-420.	4.3	26
22	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
23	α -Synuclein fate is determined by USP9X-regulated monoubiquitination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18666-18671.	3.3	154
24	Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. <i>Neurogenetics</i> , 2010, 11, 203-215.	0.7	2
25	Synphilin-1A Inhibits Seven in Absentia Homolog (SIAH) and Modulates α -Synuclein Monoubiquitylation and Inclusion Formation. <i>Journal of Biological Chemistry</i> , 2009, 284, 11706-11716.	1.6	31
26	Synphilin-1 isoforms in Parkinson's disease: regulation by phosphorylation and ubiquitylation. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 80-88.	2.4	27
27	Monoubiquitylation of α -Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 3316-3328.	1.6	153
28	Ubiquitination of α -Synuclein and autophagy in Parkinson's disease. <i>Autophagy</i> , 2008, 4, 372-374.	4.3	90
29	The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein—implications for Parkinson's disease. <i>FASEB Journal</i> , 2007, 21, 1759-1767.	0.2	48
30	Phosphorylation of Parkin by the Cyclin-dependent Kinase 5 at the Linker Region Modulates Its Ubiquitin-Ligase Activity and Aggregation. <i>Journal of Biological Chemistry</i> , 2007, 282, 12842-12850.	1.6	105
31	Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 1903-1908.	1.4	13
32	Synphilin Isoforms and the Search for a Cellular Model of Lewy Body Formation in Parkinson's Disease. <i>Cell Cycle</i> , 2006, 5, 2082-2086.	1.3	19
33	Synphilin-1A: An aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from α -Synucleinopathy patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5917-5922.	3.3	49
34	Glycogen Synthase Kinase 3 β Modulates Synphilin-1 Ubiquitylation and Cellular Inclusion Formation by SIAH. <i>Journal of Biological Chemistry</i> , 2005, 280, 42877-42886.	1.6	41
35	Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. <i>Journal of Neuroscience</i> , 2005, 25, 2002-2009.	1.7	489
36	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. <i>Neurobiology of Disease</i> , 2005, 20, 401-411.	2.1	40

#	ARTICLE	IF	CITATIONS
37	Ubiquitylation of synphilin-1 and $\hat{\alpha}$ -synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5500-5505.	3.3	177
38	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. <i>Human Molecular Genetics</i> , 2003, 12, 1223-1231.	1.4	124
39	Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. <i>NeuroReport</i> , 2003, 14, 565-568.	0.6	68
40	Synphilin-1 Is Developmentally Localized to Synaptic Terminals, and Its Association with Synaptic Vesicles Is Modulated by $\hat{\alpha}$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2002, 277, 23927-23933.	1.6	94
41	Initial stages of radial glia astrocytic transformation in the early postnatal anterior subventricular zone. <i>Journal of Neurobiology</i> , 2002, 52, 251-265.	3.7	84
42	Immunocytochemical localization of synphilin-1, an $\hat{\alpha}$ -synuclein-associated protein, in neurodegenerative disorders. <i>Acta Neuropathologica</i> , 2002, 103, 209-214.	3.9	76
43	Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by $\hat{\alpha}$ -synuclein.. <i>Journal of Biological Chemistry</i> , 2002, 277, 34651-34654.	1.6	0
44	Genetic Analysis of Synphilin-1 in Familial Parkinson's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 317-323.	2.1	18
45	No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. <i>Neuroscience Letters</i> , 2001, 307, 125-127.	1.0	18
46	A new strategy to decrease N-methyl-D-aspartate (NMDA) receptor coactivation: Inhibition of D-serine synthesis by converting serine racemase into an eliminase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5294-5299.	3.3	87
47	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. <i>Human Molecular Genetics</i> , 2001, 10, 919-926.	1.4	442
48	Synphilin-1 is present in Lewy bodies in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 521-523.	2.8	246
49	Organization of the human synphilin-1 gene, a candidate for Parkinson's disease. <i>Mammalian Genome</i> , 2000, 11, 763-766.	1.0	21
50	Human huntingtin-associated protein (HAP-1) gene: genomic organisation and an intragenic polymorphism. <i>Gene</i> , 2000, 254, 181-187.	1.0	6
51	Human serine racemase: molecular cloning, genomic organization and functional analysis. <i>Gene</i> , 2000, 256, 183-188.	1.0	137
52	Synphilin-1 is present in Lewy bodies in Parkinson's disease. , 2000, 47, 521.		1
53	Synphilin-1 is present in Lewy bodies in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 521-523.	2.8	5
54	Synphilin-1: a possible molecular determinant for Parkinson's disease. <i>Anais Da Academia Brasileira De Ciencias</i> , 2000, 72, 439-439.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Synphilin-1 associates with $\hat{1}$ -synuclein and promotes the formation of cytosolic inclusions. <i>Nature Genetics</i> , 1999, 22, 110-114.	9.4	473
56	Chromosomal localization of the Huntington Associated Protein (HAP-1) gene in mouse and humans with radiation hybrid and interspecific backcross mapping. <i>Mammalian Genome</i> , 1999, 10, 397-398.	1.0	5
57	Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. <i>Mammalian Genome</i> , 1998, 9, 565-570.	1.0	26
58	Chapter 28 Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: New answers, new questions. <i>Progress in Brain Research</i> , 1998, 117, 397-419.	0.9	35
59	Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain. <i>Human Molecular Genetics</i> , 1997, 6, 1519-1525.	1.4	114
60	Sarco/endoplasmic reticulum Ca ²⁺ -ATPase isoforms: diverse responses to acidosis. <i>Biochemical Journal</i> , 1997, 321, 545-550.	1.7	51
61	Reaction Mechanism of the Sarcoplasmic Reticulum Ca ²⁺ -ATPase. <i>Advances in Molecular and Cell Biology</i> , 1997, , 1-31.	0.1	3
62	Huntington's Disease and Dentatorubralâ€Pallidoluysian Atrophy: Proteins, Pathogenesis and Pathology. <i>Brain Pathology</i> , 1997, 7, 1003-1016.	2.1	60
63	Inhibition of creatine kinase by S-nitrosoglutathione. <i>FEBS Letters</i> , 1996, 392, 274-276.	1.3	132
64	Regulation of the channel function of Ca ²⁺ -ATPase. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1996, 1275, 105-110.	0.5	15
65	The Ca ²⁺ -ATPase Isoforms of Platelets Are Located in Distinct Functional Ca ²⁺ Pools and Are Uncoupled by a Mechanism Different from That of Skeletal Muscle Ca ²⁺ -ATPase. <i>Journal of Biological Chemistry</i> , 1995, 270, 21050-21055.	1.6	37
66	Protein interactions with a gender-specific gene of <i>Schistosoma mansoni</i> : characterization by DNase I footprinting, band shift and UV cross-linking. <i>Molecular and Cellular Biochemistry</i> , 1993, 124, 159-168.	1.4	8
67	Protein-DNA associations in a gender-specific gene of <i>Schistosoma mansoni</i> : characterization by UV cross-linking, DNase I footprinting and band shift assays. <i>Memorias Do Instituto Oswaldo Cruz</i> , 1992, 87, 67-70.	0.8	0